Literature DB >> 31005166

MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients.

M P Engbersen1, I Van' T Sant2, C Lok3, D M J Lambregts2, G S Sonke4, R G H Beets-Tan1, W J van Driel3, M J Lahaye5.   

Abstract

OBJECTIVES: To determine the diagnostic performance of MRI with diffusion-weighted imaging (DW-MRI) in assessing the peritoneal tumor load and predicting whether a complete cytoreduction can be achieved in patients with epithelial ovarian cancer (EOC).
METHODS: For this observational prospective study, 25 patients with epithelial ovarian cancer scheduled for cytoreductive surgery were included. Patients underwent a 3 T DW-MRI scan prior to surgery. The MR protocol consisted of a T1 and T2 weighted, a contrast-enhanced T1 weighted, and a diffusion-weighted (b0, b1000) sequence. The Peritoneal Cancer Index (PCI) was determined on DW-MR images (MRI-PCI) by two readers, independently, and was compared to the PCI determined during surgery (S-PCI). The inter-observer agreement between the two radiologists was evaluated. In addition, receiver operating characteristics curves were calculated for predicting complete cytoreduction with the S-PCI and MRI-PCI.
RESULTS: Staging with DW-MRI showed a correlation to surgical staging with an intraclass correlation coefficient (ICC) 0.86 and 0.85 for reader 1 and 2, respectively. Inter-observer agreement was excellent with an ICC of 0.90 (95% CI: 0.64-0.96). The MRI-PCI scores of reader 1 (AUC = 0.96), reader 2 (AUC = 0.98), and the S-PCI (AUC = 0.92) showed similar predictive values for complete cytoreduction.
CONCLUSION: DW-MRI is accurate in predicting the S-PCI and can be helpful to predict whether a complete resection in ovarian cancer patients is feasible.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Advanced-stage ovarian cancer; Cytoreductive surgery; Diffusion-weighted MRI; Peritoneal carcinomatosis

Mesh:

Year:  2019        PMID: 31005166     DOI: 10.1016/j.ejrad.2019.03.007

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  8 in total

Review 1.  The role of CT, PET-CT, and MRI in ovarian cancer.

Authors:  Maurits Peter Engbersen; Willemien Van Driel; Doenja Lambregts; Max Lahaye
Journal:  Br J Radiol       Date:  2021-09-01       Impact factor: 3.629

Review 2.  CT of Ovarian Cancer for Primary Treatment Planning: What the Surgeon Needs to Know-Radiology In Training.

Authors:  Maria Clara Fernandes; Ines Nikolovski; Kara Long Roche; Yulia Lakhman
Journal:  Radiology       Date:  2022-05-24       Impact factor: 29.146

Review 3.  Peritoneal malignancy: anatomy, pathophysiology and an update on modern day imaging.

Authors:  Jack W Power; Philip J Dempsey; Andrew Yates; Helen Fenlon; Jurgen Mulsow; Conor Shields; Carmel G Cronin
Journal:  Br J Radiol       Date:  2021-12-08       Impact factor: 3.629

4.  Chemokine Ligand 5 to Predict Optimal Cytoreduction in Ovarian Cancer.

Authors:  Yudi Mulyana Hidayat; Ali Budi Harsono; Gatot Nyarumenteng Adhipurnawan Winarno; Siti Salima
Journal:  Int J Gen Med       Date:  2020-11-20

5.  Diagnostic value of diffusion-weighted imaging/magnetic resonance imaging for peritoneal metastasis from malignant tumor: A systematic review and meta-analysis.

Authors:  Li Dong; Kuo Li; Taisong Peng
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

Review 6.  Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.

Authors:  Massimo E Maffei
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

7.  Bimodal magnetic resonance and optical imaging of extracellular matrix remodelling by orthotopic ovarian tumours.

Authors:  Filip Bochner; Liat Fellus-Alyagor; Dafna Ketter; Ofra Golani; Inbal Biton; Michal Neeman
Journal:  Br J Cancer       Date:  2020-05-11       Impact factor: 7.640

Review 8.  Diffusion-Weighted Magnetic Resonance Imaging in Ovarian Cancer: Exploiting Strengths and Understanding Limitations.

Authors:  Tanja Gagliardi; Margaret Adejolu; Nandita M deSouza
Journal:  J Clin Med       Date:  2022-03-10       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.